Faricimab, a recent FDA-approved VEGF and Ang-2 inhibitor, has been shown to work as effectively as other anti-VEGF drugs in treating wet AMD, but it does not require as many injections [50,51]. Here, VEGFA is linked to wet macular degeneration.